Division of Immunotherapy
725 West Lombard Street, Baltimore, MD 21201
Education and Training
- 2010-2015 Ph.D., Bioinformatics, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- 2015-2018 Postdoctoral, Bioinformatics, Children's National Medical Center, Washington D.C., USA
Peng Zhang received his Ph.D. in Bioinformatics from Institute of Biophysics, Chinese Academy of Sciences, and trained as a postdoctoral research associate in the Children’s National Medical Center. Peng is a faculty research associate with the Division of Immunotherapy at the University of Maryland School of Medicine. He is a computational biologist with expertise in biomedical informatics, cancer genomics, and immunogenomics. His research focuses on integrative mining and algorithm development from big data generated on high throughput techniques in tumor development, progression, drug response, and resistance.
Cancer Genomics & Immunogenomics Systematic analyses of omics-level data in the tumor microenvironment to explore immune-tumor interaction with the goal of enabling the discovery and development of more effective anti-tumor immunotherapy.
Single Cell Atlas of Immunity To create comprehensive reference maps of all human immune cells by using single-cell sequencing technology as a basis for both understanding human health and diagnosing, monitoring, and treating diseases.
Bioinformatics, Cancer Genomics, Immunogenomics, Single-Cell Sequencing
1, Zhang P#, Chou HY#, Young L, Zheng P*, Liu Y*. En masse discovery of anti-cancer human monoclonal antibodies by de novo assembly of immunoglobulin sequences from transcriptomes and genome sequences of cancer tissues. Cellular & Molecular Immunology. 2019 Dec;16(12):943-945.
2, Zhang Y#, Du X#, Liu M#, Tang F, Zhang P, Ai C, Fields J, Sundberg E, Latinovic O, Devenport M, Zheng P*, Liu Y*. Hijacking Antibody-induced CTLA-4 Lysosomal Degradation for Safer and More Effective Cancer Immunotherapy. Cell Research. 2019 Aug;29(8):609-627.
3, Zhang P, Zheng P*, Liu Y*. Amplification of the CD24 Gene is an Independent Predictor for Poor Prognosis of Breast Cancer. Frontiers in Genetics. 2019 Jun 12;10:560.
4, Tao R, Murad N, Xu Z, Zhang P, Okonechnikov K, Kool M, Rivero-Hinojosa S, Lazarski C, Zheng P, Liu Y, Eberhart CG, Rood BR, Packer R, Pei Y. MYC drives Group 3 medulloblastoma through transformation of Sox2+ astrocyte progenitor cells. Cancer Research. 2019 Apr 15;79(8):1967-1980.
5, Du X#, Liu M#, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y*, Zheng P*. Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice. Cell Research. 2018 Apr;28(4):433-447.
6, Tang F, Zhang P, Ye P, Lazarski CA, Wu Q, Bergin IL, Bender TP, Hall MN, Cui Y, Zhang L, Jiang T, Liu Y*, Zheng P*. A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1. Elife. 2017 Dec 5;6. pii: e32497.
7, Zhang P, Wu X, Basu M, Dong C, Zheng P*, Liu Y*, Sandler AD*. MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database. Frontiers in Immunology. 2017 Nov 3;8:1473.
8, Qin S#, Yin H#, Yang C, Dou Y, Liu Z, Zhang P, Yu H, Huang Y, Feng J, Hao J, Hao J, Deng L, Yan X, Dong X, Zhao Z, Jiang T, Wang HW, Luo SJ, Xie C. A magnetic protein biocompass. Nature Materials. 2016 Feb;15(2):217-26.
# co-First author, * co-Corresponding author